$NVRO
NEVRO CORP

2021 Q2 Form 10-Q Financial Statement

#000156459021040902 Filed on August 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $102.3M $56.39M
YoY Change 81.47% -39.74%
Cost Of Revenue $32.34M $19.50M
YoY Change 65.87% -34.12%
Gross Profit $69.99M $35.25M
YoY Change 98.54% -44.87%
Gross Profit Margin 68.39% 62.51%
Selling, General & Admin $73.88M $60.20M
YoY Change 22.72% -20.37%
% of Gross Profit 105.56% 170.78%
Research & Development $11.87M $10.40M
YoY Change 14.13% -30.2%
% of Gross Profit 16.96% 29.5%
Depreciation & Amortization $1.149M $1.184M
YoY Change -2.96% 6.76%
% of Gross Profit 1.64% 3.36%
Operating Expenses $85.75M $70.70M
YoY Change 21.29% -21.88%
Operating Profit -$15.76M -$35.36M
YoY Change -55.42% 33.14%
Interest Expense $5.704M -$5.200M
YoY Change -209.69% -291.88%
% of Operating Profit
Other Income/Expense, Net -$88.00K -$500.0K
YoY Change -82.4% -523.73%
Pretax Income -$21.39M -$41.00M
YoY Change -47.82% 48.21%
Income Tax $198.0K $0.00
% Of Pretax Income
Net Earnings -$21.59M -$41.06M
YoY Change -47.42% 46.54%
Net Earnings / Revenue -21.1% -72.82%
Basic Earnings Per Share -$0.62
Diluted Earnings Per Share -$0.62 -$1.209M
COMMON SHARES
Basic Shares Outstanding 34.81M
Diluted Shares Outstanding 34.81M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $397.5M $562.3M
YoY Change -29.31% 140.4%
Cash & Equivalents $146.6M $277.5M
Short-Term Investments $251.5M $285.8M
Other Short-Term Assets $8.099M $6.100M
YoY Change 32.77% -16.44%
Inventory $85.73M $91.85M
Prepaid Expenses
Receivables $65.35M $56.70M
Other Receivables $0.00 $0.00
Total Short-Term Assets $556.7M $716.9M
YoY Change -22.35% 78.91%
LONG-TERM ASSETS
Property, Plant & Equipment $18.81M $11.44M
YoY Change 64.5% -4.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.884M $4.900M
YoY Change -0.33% -59.84%
Total Long-Term Assets $42.86M $36.30M
YoY Change 18.07% -23.26%
TOTAL ASSETS
Total Short-Term Assets $556.7M $716.9M
Total Long-Term Assets $42.86M $36.30M
Total Assets $599.5M $753.2M
YoY Change -20.4% 68.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $31.03M $18.70M
YoY Change 65.93% -19.4%
Accrued Expenses $38.58M $33.87M
YoY Change 13.93% -15.02%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $164.5M
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $73.93M $220.8M
YoY Change -66.52% 233.53%
LONG-TERM LIABILITIES
Long-Term Debt $146.4M $137.3M
YoY Change 6.64% -12.16%
Other Long-Term Liabilities $20.81M $20.60M
YoY Change 1.03% -13.81%
Total Long-Term Liabilities $167.2M $157.9M
YoY Change 5.91% -12.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $73.93M $220.8M
Total Long-Term Liabilities $167.2M $157.9M
Total Liabilities $241.2M $378.7M
YoY Change -36.32% 53.63%
SHAREHOLDERS EQUITY
Retained Earnings -$544.0M -$475.7M
YoY Change 14.36% 25.78%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $358.4M $374.4M
YoY Change
Total Liabilities & Shareholders Equity $599.5M $753.2M
YoY Change -20.4% 68.13%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$21.59M -$41.06M
YoY Change -47.42% 46.54%
Depreciation, Depletion And Amortization $1.149M $1.184M
YoY Change -2.96% 6.76%
Cash From Operating Activities -$4.490M -$16.82M
YoY Change -73.31% 44.13%
INVESTING ACTIVITIES
Capital Expenditures -$4.375M -$1.160M
YoY Change 277.16% 45.0%
Acquisitions
YoY Change
Other Investing Activities $238.2M -$166.8M
YoY Change -242.83% -681.42%
Cash From Investing Activities $233.8M -$167.9M
YoY Change -239.23% -702.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -169.9M 324.8M
YoY Change -152.29% 5377.74%
NET CHANGE
Cash From Operating Activities -4.490M -16.82M
Cash From Investing Activities 233.8M -167.9M
Cash From Financing Activities -169.9M 324.8M
Net Change In Cash 59.44M 140.1M
YoY Change -57.57% 532.75%
FREE CASH FLOW
Cash From Operating Activities -$4.490M -$16.82M
Capital Expenditures -$4.375M -$1.160M
Free Cash Flow -$115.0K -$15.66M
YoY Change -99.27% 44.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
nvro Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
P6M
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-21590000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
90000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
358376000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
305000
CY2021Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2314000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4648000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11032000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
216352000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17364000
CY2020Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1187000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8483000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-24888000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1044000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
215080000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
147144000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
48340000
CY2020Q2 nvro Adjustments To Additional Paid In Capital Purchase Of Bond Hedges
AdjustmentsToAdditionalPaidInCapitalPurchaseOfBondHedges
52390000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
34933000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8357000
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1551000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4690000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10087000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-41063000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
801000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
374428000
us-gaap Profit Loss
ProfitLoss
-51151000
us-gaap Profit Loss
ProfitLoss
-65951000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2250000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2480000
nvro Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
1838000
nvro Amortization Of Operating Lease Asset
AmortizationOfOperatingLeaseAsset
1666000
us-gaap Share Based Compensation
ShareBasedCompensation
20271000
us-gaap Share Based Compensation
ShareBasedCompensation
18572000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
703000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-41000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-970000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1967000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-12000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8376000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6206000
nvro Unrealized Gains And Losses On Foreign Currency Translation
UnrealizedGainsAndLossesOnForeignCurrencyTranslation
-2006000
nvro Unrealized Gains And Losses On Foreign Currency Translation
UnrealizedGainsAndLossesOnForeignCurrencyTranslation
607000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-13111000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-23750000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
14712000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3553000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3930000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3740000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
237000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1863000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14193000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3223000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4070000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-16858000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-2075000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1751000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45203000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66329000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
146623000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
277471000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11360000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22004000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
197784000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
237017000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
488851000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
123884000
nvro Repayment From Investment In Private Company
RepaymentFromInvestmentInPrivateCompany
-7500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6935000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1993000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
284132000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-107626000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
147144000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
189750000
nvro Payments Of Convertible Notes Debt Issuance Costs
PaymentsOfConvertibleNotesDebtIssuanceCosts
6105000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
34933000
us-gaap Payments For Hedge Financing Activities
PaymentsForHedgeFinancingActivities
52390000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
172500000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5115000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2738000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6283000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
30411000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-171332000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
341005000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-20000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-233000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
101420000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
211142000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1446000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
453000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-83100000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1200000
us-gaap Net Income Loss
NetIncomeLoss
-51200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11400000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-544000000.0
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-492800000
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1868750
CY2020Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
147100000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-664000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
542000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2116000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
757000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
596000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-384000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
1598000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-534000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18142000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4220000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant accounting estimates and management judgments reflected in the condensed consolidated financial statements include items such as allowances for doubtful accounts; warranty obligations; clinical accruals; stock-based compensation; depreciation and amortization periods; inventory valuation; valuation of investments; and accounting for income taxes. Estimates are based on historical experience, where applicable, and other assumptions believed to be reasonable by the management. Actual results may differ from those estimates under different assumptions or conditions.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and investments. The majority of the Company’s cash is held by one financial institution in the United States and is in excess of federally insured limits. The Company maintained investments in money market funds that were not federally insured during the periods ended June 30, 2021 and December 31, 2020.  The Company also held cash in foreign banks of approximately $10.4 million at June 30, 2021 and $17.6 million at December 31, 2020 that was not insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three and six months ended June 30, 2021 and 2020, no single customer accounted for 10% or more of the Company’s revenue. As of June 30, 2021 and December 31, 2020, no single customer accounted for 10% or more of the accounts receivable balance.</p>
CY2021Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
10400000
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
17600000
CY2020Q2 nvro Concentration Risk Number Of Customers Exceeding Threshold
ConcentrationRiskNumberOfCustomersExceedingThreshold
0
nvro Concentration Risk Number Of Customers Exceeding Threshold
ConcentrationRiskNumberOfCustomersExceedingThreshold
0
CY2020Q2 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.10
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.10
CY2021Q2 nvro Bad Debt Expense
BadDebtExpense
200000
nvro Bad Debt Expense
BadDebtExpense
100000
CY2020Q2 nvro Bad Debt Expense
BadDebtExpense
1500000
nvro Bad Debt Expense
BadDebtExpense
2000000.0
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M20D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M25D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2746000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5618000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5892000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6069000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2792000
CY2021Q2 nvro Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
2378000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
25495000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3850000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
21645000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1333000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1234000
us-gaap Operating Lease Cost
OperatingLeaseCost
2567000
us-gaap Operating Lease Cost
OperatingLeaseCost
2468000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19162000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3876000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17425000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
16689000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
21645000
us-gaap Operating Lease Payments
OperatingLeasePayments
2506000
us-gaap Operating Lease Payments
OperatingLeasePayments
2429000
CY2021Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
99700000
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
16300000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
279746000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
52000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
43000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
279755000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
543246000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
152000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
25000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
543373000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
236721000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
236765000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
43025000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
42990000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
279746000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
279755000
CY2021Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
34821000
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
34405000
CY2021Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
50908000
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
48891000
CY2021Q2 us-gaap Inventory Net
InventoryNet
85729000
CY2020Q4 us-gaap Inventory Net
InventoryNet
83296000
CY2021Q2 nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
1500000
CY2020Q2 nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
2800000
nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
3000000.0
nvro Inventory Write Down Cash And Non Cash
InventoryWriteDownCashAndNonCash
3300000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38835000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31304000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20023000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17773000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18812000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13531000
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1149000
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1184000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2250000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2480000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25511000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
30971000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5164000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2101000
CY2021Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
749000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1191000
CY2021Q2 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
450000
CY2020Q4 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
668000
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
1295000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1548000
CY2021Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
822000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4592000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6127000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38583000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43305000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2900000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2900000
us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
limited one- to five-year warranty
CY2021Q1 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
851000
CY2021Q2 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
582000
CY2021Q2 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
611000
CY2021Q2 us-gaap Standard Product Warranty Accrual Current
StandardProductWarrantyAccrualCurrent
822000
CY2021Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2020Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
us-gaap Net Income Loss
NetIncomeLoss
-51151000
us-gaap Net Income Loss
NetIncomeLoss
-65951000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34721551
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32913947
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.00
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7212105
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9499295
CY2020Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
2400000

Files In Submission

Name View Source Status
0001564590-21-040902-index-headers.html Edgar Link pending
0001564590-21-040902-index.html Edgar Link pending
0001564590-21-040902.txt Edgar Link pending
0001564590-21-040902-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nvro-10q_20210630.htm Edgar Link pending
nvro-10q_20210630_htm.xml Edgar Link completed
nvro-20210630.xsd Edgar Link pending
nvro-20210630_cal.xml Edgar Link unprocessable
nvro-20210630_def.xml Edgar Link unprocessable
nvro-20210630_lab.xml Edgar Link unprocessable
nvro-20210630_pre.xml Edgar Link unprocessable
nvro-ex311_6.htm Edgar Link pending
nvro-ex312_7.htm Edgar Link pending
nvro-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending